Q4 2021 Results

Participants Company overview Pharmaceuticals Financial performance Oncology Innovation: Pipeline overview Our pipeline projects at a glance Financial review Conclusion Appendix Innovation: Clinical trials Phase 1/2 Phase 3 Registration Total Oncology Pharmaceuticals Cardiovascular, Renal, Metabolism 49 27 6 82 Immunology, Hepatology, Dermatology 26 CO 858 25 2 85 6 0 11 Neuroscience Ophthalmology Respiratory & Allergy Global Health 658 ∞ 8 Biosimilars 0 Total 107 95 13 121 9 1 36 0 11 1 0 7 11 0 9 0 2 54 8 169 58 Investor Relations | Q4 2021 Results 1 NOVARTIS | Reimagining Medicine

View entire presentation